(SAN) Sanofi - Ratings and Ratios
Immunology, Oncology, Neurology, Vaccines, Rare Diseases
SAN EPS (Earnings per Share)
SAN Revenue
Description: SAN Sanofi
Sanofi SA (NASDAQ: SAN) is a global, integrated healthcare company that discovers, develops, manufactures, and markets therapeutic solutions across immunology, rare diseases, neurology, oncology, and vaccines. Its vaccine portfolio spans pediatric (polio, pertussis, Hib), respiratory syncytial virus, hexavalent combination vaccines, influenza, meningitis, and travel/endemic vaccines such as hepatitis A, typhoid, yellow fever, and rabies.
The firm maintains an extensive partnership network to accelerate innovation: a licensing deal with Exscientia for up to 15 novel small-molecule candidates in oncology and immunology; collaborations with ABL Bio (alpha-synucleinopathies), Innate Pharma (NK-cell engagers), Blackstone Life Sciences (clinical development), IGM Biosciences (IgM antibodies), Kymera Therapeutics (IRAK4 degraders), Nurix Therapeutics (targeted protein degradation), Denali Therapeutics (systemic inflammatory diseases), Adagene (antibody therapeutics), Scribe Therapeutics (genome editing), and a co-promotion agreement with Provention Bio for teplizumab. A strategic alliance with Abu Dhabi’s Department of Health supports global vaccine development.
From a financial perspective, Sanofi generated €44.9 billion in revenue in 2023, with the vaccines segment contributing roughly 20 % of total sales and growing at a 6 % compound annual growth rate (CAGR) since 2020. R&D intensity remains high at ~17 % of revenue, reflecting a commitment to pipeline renewal amid a competitive biotech landscape. Key macro drivers include an aging global population, rising prevalence of chronic inflammatory diseases, and sustained demand for innovative immunotherapies and next-generation vaccines.
For a deeper quantitative assessment of SAN’s valuation and risk profile, the ValueRay platform offers a data-rich dashboard worth exploring.
SAN Stock Overview
| Market Cap in USD | 111,831m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
SAN Stock Ratings
| Growth Rating | -0.44% |
| Fundamental | 64.2% |
| Dividend Rating | 66.3% |
| Return 12m vs S&P 500 | -28.1% |
| Analyst Rating | - |
SAN Dividends
| Dividend Yield 12m | 4.52% |
| Yield on Cost 5y | 5.52% |
| Annual Growth 5y | 3.72% |
| Payout Consistency | 99.7% |
| Payout Ratio | 76.1% |
SAN Growth Ratios
| Growth Correlation 3m | -41.6% |
| Growth Correlation 12m | -66.3% |
| Growth Correlation 5y | 74.8% |
| CAGR 5y | 4.90% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.19 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.56 |
| Sharpe Ratio 12m | 0.60 |
| Alpha | 0.02 |
| Beta | 0.465 |
| Volatility | 21.00% |
| Current Volume | 4195.4k |
| Average Volume 20d | 2007.8k |
| Stop Loss | 82.6 (-3%) |
| Signal | 2.04 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (9.13b TTM) > 0 and > 6% of Revenue (6% = 2.59b TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 6.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.45% (prev 0.09%; Δ 18.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 13.31b > Net Income 9.13b (YES >=105%, WARN >=100%) |
| Net Debt (6.93b) to EBITDA (9.47b) ratio: 0.73 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.23b) change vs 12m ago -1.61% (target <= -2.0% for YES) |
| Gross Margin 71.63% (prev 67.51%; Δ 4.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.86% (prev 44.76%; Δ -10.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.14 (EBITDA TTM 9.47b / Interest Expense TTM 983.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.88
| (A) 0.06 = (Total Current Assets 37.02b - Total Current Liabilities 29.06b) / Total Assets 124.96b |
| (B) 0.55 = Retained Earnings (Balance) 68.19b / Total Assets 124.96b |
| (C) 0.06 = EBIT TTM 8.00b / Avg Total Assets 127.36b |
| (D) 1.20 = Book Value of Equity 65.54b / Total Liabilities 54.68b |
| Total Rating: 3.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.22
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 11.94% = 5.0 |
| 3. FCF Margin 27.91% = 6.98 |
| 4. Debt/Equity 0.30 = 2.46 |
| 5. Debt/Ebitda 2.19 = -0.38 |
| 6. ROIC - WACC (= 0.69)% = 0.86 |
| 7. RoE 12.39% = 1.03 |
| 8. Rev. Trend -21.62% = -1.62 |
| 9. EPS Trend -42.21% = -2.11 |
What is the price of SAN shares?
Over the past week, the price has changed by +7.14%, over one month by +0.79%, over three months by +2.54% and over the past year by -14.42%.
Is Sanofi a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SAN is around 82.39 EUR . This means that SAN is currently overvalued and has a potential downside of -3.28%.
Is SAN a buy, sell or hold?
What are the forecasts/targets for the SAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 108.2 | 27% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 90.2 | 5.8% |
SAN Fundamental Data Overview
Market Cap EUR = 95.44b (95.44b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 15.36b EUR (last quarter)
P/E Trailing = 15.2078
P/E Forward = 9.0416
P/S = 2.0866
P/B = 1.3493
P/EG = 0.7012
Beta = 0.442
Revenue TTM = 43.13b EUR
EBIT TTM = 8.00b EUR
EBITDA TTM = 9.47b EUR
Long Term Debt = 13.20b EUR (from longTermDebt, last quarter)
Short Term Debt = 7.56b EUR (from shortTermDebt, last quarter)
Debt = 20.76b EUR (Calculated: Short Term 7.56b + Long Term 13.20b)
Net Debt = 6.93b EUR (from netDebt column, last quarter)
Enterprise Value = 100.84b EUR (95.44b + Debt 20.76b - CCE 15.36b)
Interest Coverage Ratio = 8.14 (Ebit TTM 8.00b / Interest Expense TTM 983.0m)
FCF Yield = 11.94% (FCF TTM 12.04b / Enterprise Value 100.84b)
FCF Margin = 27.91% (FCF TTM 12.04b / Revenue TTM 43.13b)
Net Margin = 21.16% (Net Income TTM 9.13b / Revenue TTM 43.13b)
Gross Margin = 71.63% ((Revenue TTM 43.13b - Cost of Revenue TTM 12.24b) / Revenue TTM)
Tobins Q-Ratio = 1.54 (Enterprise Value 100.84b / Book Value Of Equity 65.54b)
Interest Expense / Debt = 1.04% (Interest Expense 216.0m / Debt 20.76b)
Taxrate = 17.82% (1.20b / 6.76b)
NOPAT = 6.58b (EBIT 8.00b * (1 - 17.82%))
Current Ratio = 1.27 (Total Current Assets 37.02b / Total Current Liabilities 29.06b)
Debt / Equity = 0.30 (Debt 20.76b / last Quarter total Stockholder Equity 70.01b)
Debt / EBITDA = 2.19 (Net Debt 6.93b / EBITDA 9.47b)
Debt / FCF = 1.72 (Debt 20.76b / FCF TTM 12.04b)
Total Stockholder Equity = 73.65b (last 4 quarters mean)
RoA = 7.30% (Net Income 9.13b, Total Assets 124.96b )
RoE = 12.39% (Net Income TTM 9.13b / Total Stockholder Equity 73.65b)
RoCE = 9.22% (Ebit 8.00b / (Equity 73.65b + L.T.Debt 13.20b))
RoIC = 7.12% (NOPAT 6.58b / Invested Capital 92.41b)
WACC = 6.43% (E(95.44b)/V(116.20b) * Re(7.64%)) + (D(20.76b)/V(116.20b) * Rd(1.04%) * (1-Tc(0.18)))
Shares Correlation 3-Years: -81.65 | Cagr: -0.92%
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.29% ; FCFE base≈8.94b ; Y1≈8.94b ; Y5≈9.49b
Fair Price DCF = 137.7 (DCF Value 167.80b / Shares Outstanding 1.22b; 5y FCF grow -0.59% → 3.0% )
EPS Correlation: -42.21 | EPS CAGR: -19.43% | SUE: -0.35 | # QB: 0
Revenue Correlation: -21.62 | Revenue CAGR: -2.57% | SUE: 1.80 | # QB: 2